# US 2013/0253191 A1 · Processes for preparing jak inhibitors and related intermediate compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253191 A1
- Document ID: US20130253191A1
- Status: Published application
- Kind: A1
- Application number: 13/761,771
- Filed: 2013-02-07
- Published: 2013-09-26
- Earliest claimed: 2009-01-15
- Assignees: Incyte Corporation
- Inventors: Jiacheng Zhou
- Web page: https://patentgrep.com/patent/US20130253191A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 7/083: {Syntheses without formation of a Si-C bond}
- C07F 7/10: containing nitrogen {having a Si-N linkage}
- C07F 7/1892: {by reactions not provided for in C07F7/1876 - C07F7/1888}
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.

## Claims

### Claim at position 1

1-99. (canceled)

### Claim 100

A process of preparing a composition comprising an enantiomeric excess of the (R)-enantiomer of a compound of Formula III′:
comprising:
(a) treating a compound of Formula XI′:
with sodium hydride and 2-(trimethylsilyl)ethoxymethyl chloride to form a compound of Formula X″:
(b) treating said compound of Formula X″ with a compound of Formula XIII′:
in the presence of Pd(triphenylphosphine)4, potassium carbonate, and a solvent, to form a compound of Formula XII″:
(c) reacting said compound of Formula XII″ under deprotection conditions to form a compound of Formula IV″:
(d) reacting said compound of Formula IV″ with a compound of Formula D-1′:
under conditions sufficient to form a composition comprising a racemate of a compound of Formula I″:
(e) passing said composition comprising said racemate of said compound of Formula I″ through a chiral chromatography unit using a mobile phase and collecting a composition comprising an enantiomeric excess of the (R)-enantiomer of said compound of Formula I″; and
(f) reacting said compound of Formula I″ with boron trifluoride diethyl etherate, followed by aqueous ammonium hydroxide to form a composition comprising an enantiomeric excess of the (R)-enantiomer of said compound of Formula III′;
wherein * is a chiral carbon.

### Claim at position 3

101-105. (canceled)

### Claim 106

A compound of Formula XII″, which is:
or a pharmaceutically acceptable salt thereof.

### Claim 107

A composition comprising an enantiomeric excess of the (R)-enantiomer of a compound of Formula I″
or a pharmaceutically acceptable salt thereof.
